Halozyme: Halozyme announces US FDA approval of argenx's Vyvgart Hytrulo prefilled syringe coformulated with ENHANZE for selfinjection for gMG and CIDP
Halozyme Therapeutics, Inc. (Halozyme) announced that argenx has received US Food and Drug Administration (FDA) approval of Vyvgart Hytrulo prefilled syringe for self─injection (efgartigimod alfa and
Read full article »
President & CEO
Helen Torley
Halozyme is a California-based biotechnology company that develops and commercializes novel therapeutics for the treatment of cancer and rare diseases.
Read more